Researchers suspect that many more genes that haven't been identified yet affect the risk of Alzheimer's disease. Such information may prove vital in the development of new ways to treat, or even prevent, Alzheimer's disease in the future. Researchers are also studying genes that may protect against Alzheimer's disease.
More research is needed to understand this variant's effect on Alzheimer's disease risk. The Alzheimer's Disease Genetics Study, sponsored by the National Institute on Aging, is examining genetic information from families that have at least two living family members who have developed Alzheimer's after age If your family is interested in participating in this study, visit the website for the National Cell Repository for Alzheimer's Disease.
A number of other studies are evaluating the genetics of people with Alzheimer's disease and their family members. To learn more about these studies, and whether or not they're recruiting volunteers, visit the National Institute on Aging's Alzheimer's Disease Education and Referral Center website, or ask your doctor what trials might be available. There is a problem with information submitted for this request.
Sign up for free, and stay up-to-date on research advancements, health tips and current health topics, like COVID, plus expert advice on managing your health. Error Email field is required. Error Include a valid email address. To provide you with the most relevant and helpful information and to understand which information is beneficial, we may combine your e-mail and website usage information with other information we have about you.
If we combine this information with your PHI, we will treat all of that information as PHI, and will only use or disclose that information as set forth in our notice of privacy practices.
You may opt-out of e-mail communications at any time by clicking on the Unsubscribe link in the e-mail. Our Housecall e-newsletter will keep you up-to-date on the latest health information. Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission. Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below. Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission.
Mayo Clinic does not endorse any of the third party products and services advertised. A single copy of these materials may be reprinted for noncommercial personal use only. This content does not have an English version. This content does not have an Arabic version. See more conditions. Alzheimer's genes: Are you at risk?
Products and services. Several genes have been associated with Alzheimer's disease, but more research is needed. By Mayo Clinic Staff. Thank you for Subscribing Our Housecall e-newsletter will keep you up-to-date on the latest health information. Please try again. Something went wrong on our side, please try again. Show references Karch CM, et al.
Alzheimer's disease genetics: From the bench to the clinic. Sherva R, et al. Genetics of Alzheimer disease. Accessed Nov. The genetics of Alzheimer's disease. Alzheimer's disease genetics fact sheet. National Institute on Aging. Carch CM, et al. By these criteria, Alzheimer disease can be sliced into four subcategories:. In reality, however, Alzheimer disease exists in a continuum, a mix of gradations across these definitions.
Also, each subtype of AD is not a pure form unto itself. Formal diagnostic texts put it at age 65; but some investigators prefer 60 and use that age in their research. Most large epidemiological studies don't assess eFAD separately with the standard tools of prevalence percentage of the population who have a disease at any given time and incidence percentage of people who get it every year because those numbers are very low, and large epidemiology studies of dementia rarely capture people below Because population-based epidemiology numbers are few and far between, scientists instead work with estimates generated from patient counts in clinical settings, and that is where the 1 to 5 percent figure comes from.
The wide range stems from local differences, such as different referral patterns and levels of specialization. Some epidemiologists note that 5 percent of all AD i.
Losing one's mental abilities at 50 is such a dramatic event that people eventually find their way to a neurological clinic and get counted, more so than when it happens in one's eighties.
On the other hand, some neurologists hesitate to diagnose AD in people under 60, driving numbers of early onset cases down. And the number of early onset cases among the tens of millions of people in the U. Given these uncertainties, researchers generally accept 2 to 3 percent of all AD i. The second criterion for measuring forms of AD—familial versus sporadic—also is more complicated than it appears at first sight. The term familial implies that at least two generations of a family have AD.
Familial AD can occur with early onset and late onset, but the precise number is unclear. That is because familial AD is not always caused by the clear-cut inheritance of a single gene, but may cluster in families by way of a more murky genetic pattern, where several unlucky genes may add up in their effects on the body to drive down AD's age of onset.
This form is more difficult to identify, and so the numbers of affected families are not accurately counted. Scientists do not fully understand the relative contributions of genetics and the environment to AD, but they believe that there is a spectrum. The later the onset of AD, the more aging and environmental factors are thought to dominate and the smaller a person's genetic predisposition appears to be. The earlier the age of onset, the more likely AD is to be driven by a deterministic, powerful mutation in a single gene that gets passed on through generations.
This kind of AD inheritance is like that of quintessential genetic diseases, such as hemophilia, or classic traits of textbook genetics, such as the color of Gregor Mendel's garden peas. The middle of the gene-environment spectrum is much more hazy, and it is the subject of intense research. Many candidate genes are being scrutinized, but none are clearly understood. Scientists do not yet know how the genes interact with one another or with environmental factors to create a burden of AD risk in a given person.
Overall, epidemiologists estimate the heritability of AD in this middle category to be approximately 80 percent. Autosomal-dominant forms of eFAD result from mutations in one of three genes. They are APP on chromosome 21, presenilin-1 on chromosome 14, and presenilin-2 on chromosome 1. Of these, presenilin-1 is by far the most common cause of eFAD. Another gene, ApoE, is known to increase the likelihood that a person will develop AD when it comes in the form known as ApoE4.
However, it does not cause autosomal-dominant disease like the three genes described above. Rather, ApoE4 is a risk factor. It is important to be aware of the difference between a deterministic mutation and a genetic risk factor. Very few carriers of known pathogenic APP or presenilin mutations live past middle age without developing AD, whereas many people who carry two ApoE4 copies do. In other words, a finding of a pathogenic APP or presenilin mutation constitutes a genetic diagnosis.
Testing for APOE-e4 is sometimes included as a part of research studies. In addition, testing for APOE-e4 is sometimes included as a part of research studies. The National Society of Genetic Counselors website provides a searchable directory to locate a counselor. With an unsupervised, at-home test, there is a real possibility of misunderstanding results, which could result in making misinformed decisions about your health.
If you are already experiencing symptoms of cognitive decline, see a health care professional for a full evaluation. Amyloid precursor protein APP , discovered in , is the first gene with mutations found to cause an inherited form of Alzheimer's. Presenilin-1 PS-1 , identified in , is the second gene with mutations found to cause inherited Alzheimer's.
Variations in this gene are the most common cause of inherited Alzheimer's. Presenilin-2 PS-2 , discovered , is the third gene with mutations found to cause inherited Alzheimer's. Apolipoprotein E-e4 APOE4 , discovered in , is the first gene variation found to increase risk of Alzheimer's and remains the risk gene with the greatest known impact.
Having this mutation, however, does not mean that a person will develop the disease.
0コメント